» Articles » PMID: 39457517

Management of Giant Thyroid Tumors in Patients with Multiple Comorbidities in a Tertiary Head and Neck Surgery Center

Overview
Journal Biomedicines
Date 2024 Oct 26
PMID 39457517
Authors
Affiliations
Soon will be listed here.
Abstract

: The thyroid gland can represent the seat of development for giant tumors exceeding 10 cm in diameter. A retrospective analysis on 21 cases of giant thyroid tumors with comorbidities, operated in the ENT Department of the Bucharest University Emergency Hospital has been conducted. : Giant benign tumors accounted for 28.57% of the cases studied and reached gigantic volumes in an average time interval of 3 years, with an average resection piece weight of 318 g. Malignant tumors accounted for 71.43%, with an average duration of evolution of 7 years, with an average resection piece weight of 581 g. : Dysphagia was present in all patients, dyspnea in 47.61% and dysphonia in 38.09% of cases. Total thyroidectomy is the gold standard in giant thyroid tumors, associated with radical neck dissection, extended to groups VI and VII in malignant tumors. In 10 of 11 cases of giant malignant thyroid tumors (90.90%), without anaplastic thyroid carcinoma, the survival at 5 years after multimodal oncologic treatment was favorable. Anticoagulant treatment increased the risk of postoperative reversible recurrent laryngeal nerve lesion. : The management of giant thyroid tumors in patients with multiple comorbidities needs a multidisciplinary team including endocrinologist, radiologist, anesthesiologist, pathologist, ENT surgeon, thoracic surgeon, oncologist and radiotherapist.

Citing Articles

Rationale for Testing TP53 Mutations in Thyroid Cancer-Original Data and Meta-Analysis.

Lacka K, Maciejewski A, Tyburski P, Manuszewska-Jopek E, Majewski P, Wieckowska B Int J Mol Sci. 2025; 26(3).

PMID: 39940804 PMC: 11817394. DOI: 10.3390/ijms26031035.


State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.

Bronowicka-Szydelko A, Rabczynski M, Dumas I, Fiodorenko-Dumas Z, Wojtczak B, Kotyra L Biomedicines. 2025; 12(12.

PMID: 39767735 PMC: 11672969. DOI: 10.3390/biomedicines12122829.


The Correlation Between Biological Markers and Prognosis in Thyroid Cancer.

Hajjar R, Duta C, Faur I, Prodan-Barbulescu C, Alhajjar H, Pantea S Biomedicines. 2025; 12(12.

PMID: 39767732 PMC: 11673981. DOI: 10.3390/biomedicines12122826.

References
1.
Birly A, Renwick A, Patel P . Recurrent cardiogenic syncope as the first presentation of thyroid carcinoma. Br J Hosp Med (Lond). 2022; 83(5):1-3. DOI: 10.12968/hmed.2021.0545. View

2.
Papaleontiou M, Norton E, Reyes-Gastelum D, Banerjee M, Haymart M . Competing Causes of Death in Older Adults with Thyroid Cancer. Thyroid. 2021; 31(9):1359-1365. PMC: 8591088. DOI: 10.1089/thy.2020.0929. View

3.
Chen R, Zhang K, Liu J, Guo L, Liu K, Geng C . Preoperative ultrasound identification and localization of the inferior parathyroid glands in thyroid surgery. Front Endocrinol (Lausanne). 2023; 14:1094379. PMC: 10009105. DOI: 10.3389/fendo.2023.1094379. View

4.
Mazumder H, Husain M, Hossain M, Mahmud S . Prevalence, trend and associated factors of obesity-related cancers among U.S. adults with metabolic syndrome: Evidence from the National Health and Nutrition Examination Survey 2001-2018. PLoS One. 2023; 18(9):e0290994. PMC: 10473473. DOI: 10.1371/journal.pone.0290994. View

5.
Salazar-Mejia C, Perez-Arredondo L . A giant mass in the neck of a young men: a case of anaplastic thyroid cancer. Pan Afr Med J. 2018; 30:151. PMC: 6201609. DOI: 10.11604/pamj.2018.30.151.15156. View